Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis-Reference-Cited by-同舟云学术

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis

Published:2021 Issue:3 Volume:13 Page:517
ISSN:2092-7355
Container-title:Allergy, Asthma & Immunology Research
language:en
Short-container-title:Allergy Asthma Immunol Res

Author:

Kim Joo-Hee¹^ORCID,Park Ji Young¹^ORCID,Jang Seung Hun¹^ORCID,Kim Jwa-Kyung²^ORCID,Song Young Rim²^ORCID,Lee Hyung Seok²^ORCID,Kim Sung Gyun²^ORCID

Affiliation:

1. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.

2. Division of Nephrology, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.

Funder

Ministry of Food and Drug Safety

National Research Foundation of Korea

Publisher

The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al

Subject

Pulmonary and Respiratory Medicine,Immunology,Immunology and Allergy

Link

https://e-aair.org/pdf/10.4168/aair.2021.13.3.517

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why is Intradialytic Hypotension the Commonest Complication of Outpatient Dialysis Treatments?;Kidney International Reports;2023-03

2. Study of the Application of Nafamostat Mesylate in Continuous Renal Replacement Therapy in Patients with Coagulation Dysfunction;Advances in Clinical Medicine;2023

3. Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis;Clinical Case Reports;2022-07

4. Nafamostat is a Potent Human Diamine Oxidase Inhibitor Possibly Augmenting Hypersensitivity Reactions during Nafamostat Administration;Journal of Pharmacology and Experimental Therapeutics;2022-06-10

5. Nafamostat;Reactions Weekly;2021-05